What Icandra Treats: Main Uses and Benefits

Icandra is indicated to help manage Type 2 Diabetes Mellitus in adults. Used as an adjunct to diet and exercise, this medication is part of a plan to help maintain appropriate blood sugar (glycaemic) levels. The primary goal of therapy is to offer support in regulating blood glucose, which is an essential part of managing chronic diabetes. The use of this medicine is a common therapeutic option for individuals needing additional support for blood sugar management.

Clinical Scenarios

The indications involve managing diabetes in adults when glycaemic control is insufficient with metformin; in those receiving vildagliptin and metformin; and in combination with other anti-diabetes medicines, such as a sulphonylurea or insulin, when further support is required.

Quick Facts

| Quick Fact: Relief for Elevated Blood Glucose |

Regulatory References

1. EMA therapeutic overview

This medication is officially designated for use only by adult patients (18 years and older) who have Type 2 diabetes mellitus. Use is specifically not recommended for the pediatric population (children and adolescents) due to a lack of safety and efficacy data, nor is it intended for patients with Type 1 diabetes.

Contraindicated Populations

Official regulatory documents classify the following conditions and populations as contraindications (must not use):

Condition/Population	Eligibility Status
Severe Renal Failure (GFR < 30 mL/min or CrCl < 60 mL/min, depending on guidance)	Contraindicated
Hepatic Impairment (including pre-treatment ALT/AST > 3 imes ULN)	Contraindicated
Acute Metabolic Acidosis (e.g., Lactic Acidosis, Diabetic Ketoacidosis)	Contraindicated
Acute Conditions that may alter kidney function or cause tissue hypoxia (e.g., severe infection, shock, recent myocardial infarction, respiratory failure)	Contraindicated
Breast-feeding (Lactation)	Contraindicated
Hypersensitivity to the active substances or excipients	Contraindicated

Restricted or Not Recommended Use

• Elderly Patients (age 65 years and older) require regular monitoring of kidney function before and during treatment.
• Use is not recommended in patients with Congestive Heart Failure (NYHA functional class III–IV).

Icandra Interactions with other medicines and products

The official interaction profile for Icandra is primarily driven by the metformin component and the risk of lactic acidosis, as documented in regulatory labeling. Interactions increasing this risk include co-administration with cationic active substances, such as cimetidine, which may delay metformin clearance by competing for renal tubular transport systems. Medicinal products that can acutely impair renal function, such as diuretics and NSAIDs, also increase this risk by reducing metformin clearance. Excessive alcohol intake is restricted due to its contribution to lactic acidosis risk. For procedures involving iodinated contrast agents, the medicine must be discontinued beforehand and restarted only after 48 hours and confirmation of normal renal function.

Pharmacodynamic interactions include an additive hypoglycaemic effect when co-administered with insulin or a sulfonylurea. Conversely, certain agents, including thiazides and corticosteroids, may reduce the medicine’s glucose-lowering effect. The vildagliptin component is noted for its low potential for metabolic interaction with CYP 450 enzymes. However, it may increase the risk of angioedema when combined with ACE inhibitors. Elderly patients require regular renal function monitoring due to the heightened risk of metformin accumulation in this population. Long-term use of metformin is also associated with interference with Vitamin B12 absorption.

How Icandra Works

The mechanism of action for Icandra, a fixed-dose combination of Vildagliptin and Metformin, is based on two complementary approaches that function to affect glucose regulation at the cellular and hormonal levels.

---

Dual Control: Inhibition of the DPP-4 Enzyme

Vildagliptin acts as a highly selective competitive inhibitor of the Dipeptidyl Peptidase-4 (DPP-4) enzyme. This mechanism prevents the rapid degradation of natural gut hormones called incretins (GLP-1 and GIP), increasing their active concentration. Elevated incretins then signal the pancreas to enhance glucose-dependent insulin release while simultaneously suppressing glucagon secretion. This action modulates the dynamic, meal-related pancreatic hormone responses.

---

Central Regulation: Modulation of Hepatic Glucose Production

Metformin acts primarily by engaging the AMPK signaling pathway in the liver, initiating this effect through the inhibition of Mitochondrial Complex I. The resulting intracellular cascade reduces the activity of key enzymes involved in gluconeogenesis, thereby modulating the flux of hepatic glucose output. This domain involves the reduction of glucose generation and the promotion of peripheral tissue response to insulin.

How to Use Icandra

Icandra is a prescription medicine formulated as a fixed-dose combination tablet intended for oral use. The administration follows a structured protocol to ensure proper use of the two active components, vildagliptin and metformin hydrochloride.

---

Official Administration Guidelines

Administration is typically structured as twice daily dosing, with one tablet taken in the morning and one in the evening. This frequency is necessary to achieve the maximum recommended daily dose of the vildagliptin component, which is 100 mg, and respect the maximum allowed dose for the metformin component, which is 2000 mg.

To help reduce common gastrointestinal effects associated with metformin, the tablet should be administered with or immediately after a meal. Tablets must be swallowed whole with water and should not be crushed or divided.

---

Population-Specific Use Adjustments

There are necessary adjustments to the usage regimen based on a patient's physiological status, particularly for organ function:

• Renal Impairment: The use of Icandra is dependent on the patient's renal function, and dose adjustment is required based on eGFR levels. Use is generally not recommended below an eGFR of 60 mL/min.
• Hepatic Impairment: Use of the medicine is not recommended in the presence of hepatic impairment.
• Pediatric Population: Safety and efficacy have not been established, and use in children and adolescents under 18 years is not recommended.

If a dose is missed, it should be taken as soon as remembered. However, patients are instructed not to take a double dose to compensate for the missed administration. This medicine is intended as a long-term therapy for managing Type 2 Diabetes Mellitus.

Research evidence / Overview of studies for Icandra

The available evidence for Icandra, a fixed-dose combination of vildagliptin and metformin, comes primarily from official governmental reviews and published scientific trials. Research has explored the medicine's role in the management of blood sugar levels in adults with Type 2 Diabetes Mellitus. The overview below summarizes the structure of this research, the types of outcomes that were monitored, and the areas where data remains limited.

---

Evidence for Initial Combination Therapy in Type 2 Diabetes

The initial use of the two active ingredients together was studied for adults who had not previously taken prescription medicine for their T2DM. Controlled trials compared the combination against taking either vildagliptin or metformin alone, or against an inactive substance. These studies monitored outcomes related to systemic imbalance, specifically looking at changes in blood sugar markers like Glycated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG).

The research so far describes patterns in which blood sugar measurements were observed to be different in the combination groups compared to the monotherapy or placebo groups. Some trials monitored the proportion of observed patients who reached pre-defined blood sugar targets. Follow-up data, including an extended trial on initial combination therapy, contributes to the broader evidence landscape by showing the duration over which blood sugar measurements were observed.

---

Evidence for Adding Icandra When Metformin Alone Is Insufficient

Controlled trials and observational studies evaluated the use of Icandra when patients were observed to be already taking metformin but required additional support. These studies examined additional changes in the HbA1c and FPG outcomes. The study populations were adults whose T2DM was associated with insufficient blood sugar control despite receiving their maximum tolerated dose of metformin.

Studies report how symptoms evolved in the observed populations, describing additional changes in HbA1c measurements when vildagliptin was introduced to the metformin regimen, compared to the addition of a placebo. A key limitation is that comparative evidence is lacking for the FDC against every other drug class that may be added to metformin monotherapy.

---

What Remains Uncertain: Research Gaps and Areas for Future Study

The current body of research primarily focuses on studies monitoring changes in blood sugar markers over short and intermediate periods. Key limitations of this research include that follow-up durations were limited in many triple therapy studies. Also, data for certain groups remain insufficient, particularly those with severely reduced kidney function (GFR <30 mL/min), who were often excluded from the initial trials. The longer-term effects of this specific combination on the most important outcomes, such as macrovascular or microvascular outcomes, are not fully established.

Key Studies & References

1. Efficacy and safety of vildagliptin combined with metformin in the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis

Common questions about Icandra (FAQ)

Q: How long does the effect of one dose of Icandra usually last?

A: The medicine is typically prescribed for twice daily administration, with one dose taken in the morning and one in the evening. This approach is described as supporting the medicine’s effect on blood sugar control throughout a 24-hour period, according to the official product information.

---

Q: Do side effects of Icandra go away after the first few days?

A: Regulatory documents note that the very common side effects involving the stomach and intestines, such as nausea or diarrhea, often occur at the start of treatment. The symptoms of rare, documented cases of hepatic dysfunction were described as resolving.

---

Q: Does Icandra interact with common over-the-counter medications like Ibuprofen or Tylenol?

A: The official product information lists interactions for certain types of pain relief medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), due to their potential effects on kidney function. While paracetamol (Tylenol) is not listed as a formal drug interaction in the regulatory labels, official guidance recommends consulting the prescribing healthcare provider about taking any new medicine or supplement.

---

Q: Why is Icandra available in different strengths?

A: The medicine is a fixed-dose combination and is available in different strengths (e.g., 50 mg/850 mg and 50 mg/1000 mg). The availability of different strengths is described as supporting the appropriate dose matching of the metformin component for the patient’s overall regimen.

---

Q: Is Icandra an antibiotic?

A: No. Icandra is not an antibiotic. It is classified as a combination medicine consisting of a DPP-4 inhibitor (vildagliptin) and a biguanide (metformin), and it is used exclusively to manage Type 2 Diabetes Mellitus.

---

Q: Is it normal to feel tired or sleepy when starting Icandra?

A: Official safety documents list dizziness and tremor as commonly reported nervous system effects. Additionally, asthenia (a lack of energy or weakness) is listed as a common side effect when the medicine is used as part of a triple combination therapy.

---

Q: Can Icandra cause weight gain or loss?

A: Studies and official information indicate that vildagliptin, one of the active substances, is described as being generally weight neutral. This means it does not typically cause either significant weight gain or loss when used in combination with other diabetes medicines.

---

Q: Where can I find the official research evidence for Icandra?

A: The comprehensive scientific discussion and data review for the medicine are contained within official documents from regulatory agencies. These resources include the European Public Assessment Report (EPAR) and the EMA Assessment Report.

---

Q: Is Icandra similar to other drugs that treat the same condition?

A: Yes, Icandra belongs to the broad therapeutic group of oral blood-glucose-lowering drugs. Its combination of a DPP-4 inhibitor and a biguanide acts through dual mechanisms to manage Type 2 Diabetes.

---

Q: Do official documents mention any effects of Icandra on fertility or planning pregnancy?

A: Official documents state that no specific studies on the effect on human fertility have been conducted for this medicine. Furthermore, regulatory product information states that the medicine is contraindicated for use during pregnancy.

---

Q: How long has Icandra been approved and on the market?

A: The fixed-dose combination containing vildagliptin and metformin was first approved in the European Union in November 2007. The marketing authorization for the specific brand name Icandra was granted shortly thereafter in December 2008.

---

Q: Can Icandra affect my ability to drive or operate machinery?

A: The official product information states that caution is warranted when driving or operating machinery. This is because patients may experience side effects such as dizziness or the effects of hypoglycemia (low blood sugar), which could affect concentration.

---

Q: Are there differences in Icandra's effects based on a person's age or gender?

A: Regulatory documents indicate that the required monitoring of renal function used to determine eligibility and safe use may affect prescribing across different patient populations, including those of various ages and genders.

---

Q: Are there different brand names for the medicine Icandra?

A: Yes. The combination of the active substances, vildagliptin and metformin, is marketed under several different trade names globally. Examples of these alternative names include Eucreas and Zomarist.

---

Q: Can I take vitamins or supplements with Icandra?

A: The metformin component is officially associated with interference with the absorption of Vitamin B12, which may require patient monitoring. No specific guidance is provided in the official documents on taking other general vitamins or supplements, and consultation with a healthcare provider is recommended for clarity.

---

Q: Why is Icandra sometimes described as a 'novel' drug?

A: The vildagliptin component of the medicine is one of the active substances that belongs to a relatively new class of oral anti-diabetic drugs called DPP-4 inhibitors. This newer mechanism of action contributes to the medicine being described as a newer therapy.

Icandra (vildagliptin/metformin hydrochloride) must be stored and disposed of according to official regulatory labeling to ensure product stability and safety.

Storage Conditions

Requirement	Official Statement
Temperature	Store below 30 C or at controlled room temperature.
Protection	Store in the original package (blister) to protect the tablets from moisture and light.
Child Safety	Keep this medicine out of the sight and reach of children.
Expiration	Do not use the medicine after the expiry date (EXP) stated on the packaging.

Disposal Requirements

Expired or unused medicine must be disposed of properly. Do not throw away any medicines via wastewater or household waste. Patients should ask the pharmacist how to throw away medicines you no longer use, as specific measures help protect the environment.